Published in Liver Int on July 10, 2012
Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects. World J Gastroenterol (2014) 0.88
Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int (2014) 0.87
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol (2015) 0.82
Arrhythmia risk in liver cirrhosis. World J Hepatol (2015) 0.79
Cirrhotic cardiomyopathy: Isn't stress evaluation always required for the diagnosis? World J Hepatol (2016) 0.78
Does cirrhotic cardiomyopathy exist? 50 years of uncertainty. Clin Res Cardiol (2013) 0.76
Cirrhotic cardiomyopathy: Implications for the perioperative management of liver transplant patients. World J Hepatol (2015) 0.76
Bradycardia induced polymorphic ventricular tachycardia during living donor liver transplantation. Indian J Anaesth (2016) 0.75
Risk factors for QT interval prolongation owing to acute gastrointestinal haemorrhage in patients with cirrhosis. Liver Int (2012) 0.75
Diastolic dysfunction in cirrhosis. Heart Fail Rev (2016) 0.75
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology (2012) 2.46
Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology (2012) 2.38
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis (2011) 2.14
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2012) 2.00
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol (2004) 1.83
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol (2010) 1.70
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol (2004) 1.67
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol (2010) 1.45
Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut (2010) 1.44
Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol (2007) 1.30
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut (2010) 1.29
Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol (2010) 1.22
Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis (2009) 1.18
Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology (2013) 1.17
Hepatitis B virus-related hepatocarcinogenesis: molecular oncogenic potential of clear or occult infections. Eur J Cancer (2010) 1.15
Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol (2007) 1.14
The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol (2011) 1.11
A novel model of CCl4-induced cirrhosis with ascites in the mouse. J Hepatol (2009) 1.10
Posttransplantation lymphoproliferative disorders. Arch Intern Med (2003) 1.09
Relationship between ghrelin levels, alcohol craving, and nutritional status in current alcoholic patients. Alcohol Clin Exp Res (2006) 1.09
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma. Am J Gastroenterol (2006) 1.08
Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol (2006) 1.08
The reduced tolerance of rat fatty liver to ischemia reperfusion is associated with mitochondrial oxidative injury. J Surg Res (2005) 1.05
Interactions of the heart and the liver. Eur Heart J (2013) 1.04
Regional cerebral hypoperfusion in patients with celiac disease. Am J Med (2004) 1.03
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis (2013) 1.02
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. Stem Cells (2006) 1.01
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut (2011) 1.00
Alcohol use in adults. N Engl J Med (2013) 0.99
Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med (2002) 0.98
The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab (2009) 0.97
Stem cells for end stage liver disease: how far have we got? World J Gastroenterol (2008) 0.96
Acute Liver Failure Caused by Amanita phalloides Poisoning. Int J Hepatol (2012) 0.95
The MELD score in patients awaiting liver transplant: strengths and weaknesses. J Hepatol (2010) 0.94
Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl (2010) 0.93
QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol (2003) 0.92
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol (2007) 0.92
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis. Lab Invest (2011) 0.92
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol (2007) 0.90
Clinical indications for the albumin use: still a controversial issue. Eur J Intern Med (2013) 0.90
Spontaneous Cholecystocutaneous Fistula. Case Rep Gastroenterol (2010) 0.90
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol (2005) 0.89
Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology (2014) 0.88
Virus-specific immune response in HBeAg-negative chronic hepatitis B: relationship with clinical profile and HBsAg serum levels. PLoS One (2013) 0.88
Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int (2012) 0.88
Role of contrast-enhanced ultrasonography in primary hepatic lymphoma. J Ultrasound Med (2010) 0.88
Medications acting on the GABA system in the treatment of alcoholic patients. Curr Pharm Des (2010) 0.88
The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. Liver Int (2013) 0.87
Reduced prevalence of ischemic events and abnormal supraortic flow patterns in patients with liver cirrhosis. Liver Int (2005) 0.87
Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clin Chem Lab Med (2013) 0.87
Sudden unexpected fatal encephalopathy in adults with OTC gene mutations-Clues for early diagnosis and timely treatment. Orphanet J Rare Dis (2014) 0.87
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol (2008) 0.86
Interaction of alcohol intake and cofactors on the risk of cirrhosis. Liver Int (2010) 0.86
C-11 acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. Clin Nucl Med (2009) 0.86
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol (2011) 0.86
Liver transplantation from donors aged 80 years and over: pushing the limit. Am J Transplant (2004) 0.86
Alcohol use disorders in the elderly: a brief overview from epidemiology to treatment options. Exp Gerontol (2012) 0.85